Transform your drug development journey with Certara’s comprehensive solutions. From molecule to market, we seamlessly integrate science, technology, strategic and regulatory expertise to solve your unique challenges.
Discover more
Unify insights to accelerate drug development and achieve development milestones. Partner with Certara to unlock your pipeline’s potential.
Learn moreCertara’s software solutions offer transformative approaches across all drug development phases, aligning with recognized industry standards. By integrating advanced modeling, analytics, and automation, they break down silos, streamline workflows, and drive regulatory success.
View allTransform drug development with our tailored services. From predictive modeling to market access strategies, Certara’s integrated services enhance decision-making, streamline processes, and make your drug a safer bet.
View allCertara tailors solutions for biotech, pharma, and CROs, addressing unique challenges to drive success.
Learn who we work with
Certara collaborates with leading biotech, pharma, and CRO partners to tackle complex challenges, deliver innovation, and shape the future of healthcare.
Learn moreWith over 1,000 articles spanning categories and solutions, Certara’s resources is a geek haven. It’s all here—built for scientists who dare to think different.
View allWith over 1,550+ employees in more than 30 countries, over 28% of which have PhDs, our vision is to transform drug development for good.
Learn more about us
Join a global leader transforming the future of drug development. Explore opportunities to innovate, grow, and make a difference in transforming lives.
Visit careers siteHome / Publication / Treatment patterns of patients with HR+/HER2- metastatic breast cancer receiving CDK4/6 inhibitor-based regimens: a cohort study in the French nationwide healthcare database
To assess real-world treatment patterns in patients diagnosed with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer (mBC) who received cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in …
Author(s): Stephanie H. Read, Nadia Quignot, Raissa Kapso-Kapnang, Erin Comerford, Ying Zheng, Corona Gainford, Medha Sasane, Anne-Lise Vataire, Laure Delzongle & Francois-Clement Bidard
Year: January 11, 2024
Why sign up? Because transforming drug development is not just our goal—it’s our obsession. If it’s yours too, then be the first to know of new insights and join us in pushing the boundaries of science.
© 2025 Certara. All Rights Reserved. | Privacy policy
